<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/0FED1C47-231B-46E3-9C8D-2CE5528F10B1"><gtr:id>0FED1C47-231B-46E3-9C8D-2CE5528F10B1</gtr:id><gtr:name>The Karolinska Institute, Stockholm</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/7BC6FCF2-358C-45C5-A5A7-E859DD754711"><gtr:id>7BC6FCF2-358C-45C5-A5A7-E859DD754711</gtr:id><gtr:name>Lund University</gtr:name><gtr:address><gtr:line1>Box 117</gtr:line1><gtr:line2>S-221 00</gtr:line2><gtr:line4>Lund</gtr:line4><gtr:postCode>S-221 00</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/1354C618-9C7F-4E90-97AE-2A04B4C8536D"><gtr:id>1354C618-9C7F-4E90-97AE-2A04B4C8536D</gtr:id><gtr:name>Cancer Research UK (CRUK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/A400BE25-0A67-4DC4-90E2-F3C57C400F4D"><gtr:id>A400BE25-0A67-4DC4-90E2-F3C57C400F4D</gtr:id><gtr:name>Technion Israel Institue of Technology</gtr:name><gtr:address><gtr:line1>Taub Building</gtr:line1><gtr:line2>Technion  Institute of Technology</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Israel</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Institute of Neurology</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/0FED1C47-231B-46E3-9C8D-2CE5528F10B1"><gtr:id>0FED1C47-231B-46E3-9C8D-2CE5528F10B1</gtr:id><gtr:name>The Karolinska Institute, Stockholm</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/7BC6FCF2-358C-45C5-A5A7-E859DD754711"><gtr:id>7BC6FCF2-358C-45C5-A5A7-E859DD754711</gtr:id><gtr:name>Lund University</gtr:name><gtr:address><gtr:line1>Box 117</gtr:line1><gtr:line2>S-221 00</gtr:line2><gtr:line4>Lund</gtr:line4><gtr:postCode>S-221 00</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/1354C618-9C7F-4E90-97AE-2A04B4C8536D"><gtr:id>1354C618-9C7F-4E90-97AE-2A04B4C8536D</gtr:id><gtr:name>Cancer Research UK (CRUK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/A400BE25-0A67-4DC4-90E2-F3C57C400F4D"><gtr:id>A400BE25-0A67-4DC4-90E2-F3C57C400F4D</gtr:id><gtr:name>Technion Israel Institue of Technology</gtr:name><gtr:address><gtr:line1>Taub Building</gtr:line1><gtr:line2>Technion  Institute of Technology</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Israel</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/7ADD968D-1D63-4687-B530-A7EC95C89DDF"><gtr:id>7ADD968D-1D63-4687-B530-A7EC95C89DDF</gtr:id><gtr:firstName>Sarah</gtr:firstName><gtr:otherNames>Joanna</gtr:otherNames><gtr:surname>Tabrizi</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/F68DA95A-5C35-4818-A166-41EAD0AB875D"><gtr:id>F68DA95A-5C35-4818-A166-41EAD0AB875D</gtr:id><gtr:firstName>Robert</gtr:firstName><gtr:surname>Goold</gtr:surname><gtr:roles><gtr:role><gtr:name>RESEARCHER</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/DA21EBE3-9FCC-412D-894A-7EFF05EF4286"><gtr:id>DA21EBE3-9FCC-412D-894A-7EFF05EF4286</gtr:id><gtr:firstName>Giampietro</gtr:firstName><gtr:surname>Schiavo</gtr:surname><gtr:orcidId>0000-0002-4319-8745</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=MR%2FJ003832%2F1"><gtr:id>DEC66B6C-8688-4DF2-9D2B-4A4BBFCD974B</gtr:id><gtr:title>Cellular pathophysiology of prion-mediated neurodegeneration - a model for understanding protein misfolding disorders</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/J003832/1</gtr:grantReference><gtr:abstractText>In the 1990s, scientists made a connection between bovine spongiform encephalopathy (BSE or &amp;quot;mad cow disease&amp;quot;) and the fatal brain disorder variant Creutzfeldt-Jakob disease (vCJD) in humans. This discovery raised the profile of prion diseases both in the UK and internationally due to the associated public health and economic concerns. Rather than bacteria or viruses, prion diseases are caused by a rogue form of one our own proteins (prion protein), which accumulates in the central nervous system, leading to progressive brain cell malfunction and ultimately brain cell death. In patients, these changes appear as a rapidly advancing dementia, where memory, movement, balance and personality are all affected. In the absence of any effective treatment for prion disease sufferers, there is a clear need to study how the rogue prion protein leads to irreversible brain damage. It is becoming increasingly clear that the mechanisms underlying prion diseases are also observed in more common dementias such as Alzheimer's disease and Parkinson's disease. Our research therefore aims to investigate these similar pathways with the goal of identifying new drug targets for the treatment of all neurodegenerative conditions. 

Previous work in our laboratory has identified that the rogue prion protein is able to block the cell's waste-processing centre (a structure known as the proteasome). Under normal conditions, the proteasome removes old or abnormally folded proteins from nerve cells to ensure they do not accumulate to toxic levels. By monitoring mice infected with prions we have observed that this disruption in cellular waste-processing occurs very early in disease progression. This suggests that drugs aimed at preserving this function in nerve cells could be candidates for future prion disease therapy. Our research therefore aims to answer two important questions: firstly, how do rogue prion proteins enter and move round inside the brain cells to disrupt normal waste-processing and secondly, what are the downstream consequences which lead to brain cell damage? The team uses a wide range of methods to answer these questions, including the detailed study of isolated cells and prion-infected laboratory mice. By furthering our understanding of how rogue prion proteins move around inside and damage the brain cells they infect, we hope to design treatments which aim to slow or prevent the onset of clinical symptoms in patients with prion disease and related neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease and Huntington's disease where similar pathways to nerve cell death exist.</gtr:abstractText><gtr:technicalSummary>Prion diseases are fatal neurodegenerative disorders whose pathogenesis is associated with a conformational rearrangement of the normal cellular PrP (PrPC) to abnormal conformers (PrPSc) which causes neurodegeneration via a poorly defined mechanism. Understanding these mechanisms has key relevance to other neurodegenerative proteinopathies where both prion-like mechanisms and dysfunction of the proteostasis networks have been suggested to be important. My laboratory has demonstrated that dysfunction of the ubiquitin proteasome system (UPS) is an early event in prion disease pathogenesis in vivo, and that beta-sheet rich PrP oligomers potently inhibit proteasome activity in vitro. Work from my last MRC grant yielded a novel cell model where PrP knockdown neuroblastoma cells have been engineered to express an epitope-tagged PrP-chimera (PrP-Ala224MYC). This novel chimera is unique since it supports prion replication, and generates bona fide epitope-tagged PrPSc. We have used this model system to study the earliest events in prion infection. This proposal has five main aims directed at extending the understanding of the cellular pathobiology of prion disease. Our existing PrP-Ala224MYC cell model will be used to map the cellular trafficking pathways of PrPSc with a view to defining how it accesses the cytosol. We will reconstitute neuronal stem cells derived from PrP KO mice with PrP-Ala224MYC, to study prion formation, UPS dysfunction and cytotoxicity in neurons. Detailed biochemical studies will refine our molecular understanding of the inhibitory interaction between misfolded PrP and the UPS. Lentiviral-mediated knockdown of PrP in vivo will determine whether UPS activity can be modulated in neurons as a viable therapeutic target. A proteomic study of the ubiquitinated proteome in prion-diseased brain will identify substrate proteins that accumulate as the disease progresses with the aim of uncovering new pathways that may contribute to cellular toxicity.</gtr:technicalSummary><gtr:potentialImpactText>Neurodegenerative disease is set to have a serious and long-term impact on UK society, extending from the immeasurable burden on the lives of those affected to the wider social and economic implications of long-term care. The Dementia 2010 report estimated that neurodegenerative disease costs the UK economy &amp;pound;23 billion per year, greater than the cost of cancer (&amp;pound;12 billion/year) and heart disease (&amp;pound;8 billion/year) combined. To limit the inexorable rise in healthcare spending, research into neurodegeneration must uncover the sub-cellular mechanisms of disease to aid the design of rational therapeutics. Due to the irreversibility of neuronal loss, future therapies will need to target the pre-degenerative disease state, which is associated with subtle alterations in cellular function. Our research into the ubiquitin-proteasome system (UPS) has identified it as one of the earliest targets of prion-disease pathology. The proposed research will therefore investigate the relationship between misfolded proteins and the UPS to determine its validity as a therapeutic target. This research is of key interest to the pharmaceutical industry which, despite significant investment, has failed to date to develop effective disease-modifying treatments for patients with neurodegenerative diseases. By guiding the development of treatments for early stage dementia, our findings could help to shift public health policy away from long-term care and towards disease prevention. 
 
Each of the specific research aims outlined in the scientific case for support will promote the development of new and innovative methodologies. For instance, the proposed research will continue to develop our novel engineered PrP chimera by using it to generate post-mitotic primary neuronal cultures which express a tagged PrPSc. Successful generation of this cell line will allow researchers to track the earliest sources of cellular toxicity following protein-misfolding - a key question which currently remainsanswered. Altered trafficking of misfolded proteins has been suggested to be of importance in several neurodegenerative diseases (e.g. Alzheimer's, Huntington's and Parkinson's diseases) and therefore the experiments designed to dissect key trafficking pathways in prion toxicity will have relevance to these more common diseases. Thus despite being rooted in the basic mechanisms of prion disease, the research has the potential to influence academic research groups investigating other neurodegenerative diseases. In vivo models of AD, PD and HD require the expression of human mutant proteins, often with variable recapitulation of the human disease phenotype. In contrast, laboratory mice infected with prions genuinely succumb to prion disease, allowing us to identify which pathological mechanisms may be relevant to disease progression. Advances in understanding prion pathophysiology could therefore have major implications for other protein-misfolding disorders through the elucidation of common cellular mechanisms. 

The stimulating research environment at the Institute of Neurology will train and deliver highly skilled researchers with the expertise and knowledge to investigate cellular mechanisms of pathology across a wide spectrum of neurodegenerative conditions. We recognise that there is an increasing demand to communicate research progress to the general public, in particular patients and their families. Through our public communication plans (see Pathways to Impact), we hope to provide reassurance that current research efforts are successfully dissecting complex disease aetiologies to identify new treatment options.</gtr:potentialImpactText><gtr:fund><gtr:end>2016-02-29</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>490801</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London (KCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Medicine KCL</gtr:department><gtr:description>Professor Gillian Bates</gtr:description><gtr:id>54363923-1E8F-4AE4-AE89-6B55C07073AF</gtr:id><gtr:impact>Gill Bates - she has been collaborating with Gill Bates since 2000&amp;nbsp;and is co-applicant on another MRC grant with Gill Bates: 3 papers from 2006 are: Tsang T, Woodman B, McGloughlin G, Griffin J, Tabrizi SJ, Bates GP, Holmes E. Metabanomic Characterisation of the R6/2 Transgenic Mouse Model of Huntington's Disease by High-Resolution MAS 1H NMR spectroscopy. Journal of Proteome Research. 2006 Mar;5(3):483-92. Alexandra Zourlidou, Tali Gidalevitz , Mark Kristiansen , Ben Woodman, Dominic J. Wells, David S. Latchman, Jackie de Belleroche, S. J. Tabrizi, Richard I. Morimoto and Gillian P. Bates. Hsp27 overexpression in the R6/2 mouse model of Huntington's Disease: Chronic Neurodegeneration does not Induce Hsp27 Activation. Human Molecular Genetics. Epub 2007 Mar 14. 2007 May 1;16(9):1078-90. Annette Dalrymple, Edward J Wild, Richard Joubert, Kirupa Sathasivam, Maria Bj&amp;ouml;rkqvist, &amp;Aring;sa Peters&amp;eacute;n, Jeremy Isaacs, Mark Kristiansen, Gillian P Bates Blair R Leavitt, Geoff Keir, Malcolm Ward, S. J Tabrizi. Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and candidate biomarkers Journal of Proteome Research. 2007 Jul;6(7):2833-40. 2008 -2011 Identification and Cross-validation of Early Stage Phenotypes in Mouse Models of Huntington's disease. Ref G0800846 - MRC - Models of Disease grant. Co-applicant with Professor Gillian Bates (PI) and Dr Michael Modeo (co-applicant). &amp;pound;910,736</gtr:impact><gtr:partnerContribution>I was co-applicant on this grant. As well as funding there was intellectual contribution and reagents</gtr:partnerContribution><gtr:piContribution>Intellectual Contribution and Reagents. Running in vivo aspects of the project.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Karolinska Institute</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:department>Department of Cell and Molecular Biology</gtr:department><gtr:description>Nico Dantuma Group</gtr:description><gtr:id>44D2A3E4-5686-45B5-A6A3-EF8C9C116BC7</gtr:id><gtr:impact>Sarah has a paper with Nico Dantuma. &amp;nbsp;She says she has been collaborating with him from 2006: M Kristiansen, P Deriziotis, D Dimcheff, GS. Jackson, H Ovaa, H Naumann, F Leeuwen, V Benito, AR Clarke, NP Dantuma, JL Portis, J Collinge, SJ Tabrizi.&amp;nbsp; Disease associated prion protein oligomers inhibit the 26S proteasome. Molecular Cell. 2007 Apr 27;26(2):175-88.&amp;nbsp;</gtr:impact><gtr:partnerContribution>Intellectual contribution and reagents</gtr:partnerContribution><gtr:piContribution>Intellectual contribution and reagents</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Lund University</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>Dr Maria Bjorkqvist</gtr:description><gtr:id>1B847458-9BCC-472E-BDF1-4DCA4BE5302A</gtr:id><gtr:impact>18625748</gtr:impact><gtr:partnerContribution>Intellectual contribution and reagents</gtr:partnerContribution><gtr:piContribution>Intellectual contribution and reagents</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Technion - Israel Institute of Technology</gtr:collaboratingOrganisation><gtr:country>Israel, State of</gtr:country><gtr:department>Faculty of Biology</gtr:department><gtr:description>Professor Michael Glickman</gtr:description><gtr:id>57B97FB9-2A94-4CB4-AF72-65EC649E6FF8</gtr:id><gtr:impact>Co-author of paper in EMBO Journal 2011 (Misfolded PrP impairs the UPS by interaction with the 20S proteasome and inhibition substrate entry).</gtr:impact><gtr:partnerContribution>Intellectual contribution and reagents.</gtr:partnerContribution><gtr:piContribution>Intellectual contribution and reagents</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Harvard University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Harvard Medical School</gtr:department><gtr:description>Professor Alfred Goldberg</gtr:description><gtr:id>E1A1BDE4-0766-48D0-BB05-1032F2C608A1</gtr:id><gtr:impact>Co-author of published paper in EMBO Journal, 2011 (Misfolded PrP impairs the UPS by interaction with the 20S proteasome and inhibition of substrate entry).</gtr:impact><gtr:partnerContribution>Intellectual contribution and reagents</gtr:partnerContribution><gtr:piContribution>Intellectual contribution and reagents</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK (CRUK)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Professor Giampietro Schiavo</gtr:description><gtr:id>3E546382-76D1-4BC8-9ED4-5AE944D198A0</gtr:id><gtr:impact>Co-author of paper in Nature Communications, published in 2011 

Goold R, Rabbanian S, Sutton L, Andre R, Arora P, Moonga J, Clarke AR, Schiavo G, Jat P, Collinge J, Tabrizi SJ. Rapid cell-surface prion protein conversion revealed using a novel cell system. Nature Communications. 2011;2:281.

Goold R, McKinnon C, Rabbanian S, Collinge J, Schiavo G, Tabrizi SJ. Alternative fates of newly formed PrPSc upon prion conversion on the plasma membrane. Journal of Cell Science. 2013 Aug 15; 126(Pt 16):3552-62.</gtr:impact><gtr:partnerContribution>Intellectual contribution and reagents.</gtr:partnerContribution><gtr:piContribution>Intellectual contribution and reagents.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>MRC Centre for Neuromuscular Diseases Seminar Series 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>13A08F51-1E15-417E-B090-C245AB9D493D</gtr:id><gtr:impact>Presented talk on therapeutic strategies in HD to students and professional practitioners alike. The talk generated lot's of interest and questions.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>North Thames UK Dementia &amp; Neurodegenerative Disease network</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>17BAB96D-6CB6-47CB-AB3C-211BFEB9BD4F</gtr:id><gtr:impact>Well attended

Good for work</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Article in the Lancet by Priya Shetty,  Vol 379 June 2, 2012</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>14D24FD7-9EF6-4660-9500-8252EF49D478</gtr:id><gtr:impact>Articles of this nature serve to enhance engagement with my research

Various</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.thelancet.com</gtr:url><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NIND Workshop on HD Biomarkers</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B8EDCE5A-7147-4BFE-86C7-CA384CA99B92</gtr:id><gtr:impact>NIND Workshop on HD Biomarkers held in Maryland, USA in February 2013

Various</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.ninds.nih.gov/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Brains Talk Seminar at Roche</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F6F236E0-49B1-4AC5-8BBA-2DE916AFD015</gtr:id><gtr:impact>Presented seminar on Hutington's Disease to Roche Pharmaceuticals to aid company strategic planning</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Plenary Lecture - CIBERNED Annual Meeting co-organized by the Reina Sofia Foundation, Madrid</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>585F2E3F-A07C-4F2B-8AC8-9B7E08B62662</gtr:id><gtr:impact>Invitations and talks of this nature serve to enhance engagement with my research

Various</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.nadproject.eu/events-a-news.html</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CAG Triplet Repeat Disorders, Tuscany, Italy</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B5B54B94-FA61-403E-9A15-689192A0B544</gtr:id><gtr:impact>Presented talk on HD research to scientific peers and healthcare professionals</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presented talk at 28th Cambridge Neuroscience Seminar, Cambridge University</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>A4FF9EC7-992F-4270-8AA0-C41778B5C728</gtr:id><gtr:impact>Presented talk entitled 'Meeting the therapeutic challenge in Huntington's disease'</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>First Scientific Conference of International Progressive Multiple Sclerosis Collaborative</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>43159D13-71BC-448D-A603-EAFC747D64F2</gtr:id><gtr:impact>First Scientific Conference of International Progressive Multiple Sclerosis Collaborative held in Milan in February 2013

No</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:url>http://www.msif.org/global-ms-news/msif-news/progressive-ms-meeting-in-milan.aspx</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presented talk at Huntington Study Group Conference and Satellite Symposium, Nashville</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5A66304E-88EE-4180-B039-FAF9C159FD80</gtr:id><gtr:impact>Presented talk entitled &amp;quot;Neuroimaging endpoints for HD studies and Track-HD data&amp;quot;. Talk generated questions and audience discussion</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invitation to Guest Lecture at Edinburgh Clinical Neurosciences Academic Lecture Series, October 2012, Edinburgh.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>C10C9E50-5FD2-4A34-AF83-2CE38A4D4FD1</gtr:id><gtr:impact>Well attended

Very good</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CHDI 10th Annual HD Therapeutics Conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>FCF4E5A1-491A-40B5-A7D6-DEE65A13547D</gtr:id><gtr:impact>Presented talk on HD studies to researchers, healthcare practitioners and students.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presented talk at Imperial College Neuroscience Society's Conference 2017</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>DE9AECAE-AFC0-49D1-8F39-00D22B334D1A</gtr:id><gtr:impact>Presented talk titled 'Meeting the therapeutic challenge in Huntington's disease'. Generated questions and audience discussion</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Festival of Neuroscience - BNA meeting</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>ED318C83-7271-4F14-BFDF-EA6053F89CE3</gtr:id><gtr:impact>Invitations and talks of this nature serve to enhance engagement with my research

Various</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:url>http://www.bna2013.com/207037</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>2013 World Congress on Huntington's Disease - WCHD - 13</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>FAB7F6C8-1D9B-4F51-93BC-52F61ADEB926</gtr:id><gtr:impact>Invitations and talks of this nature serve to enhance engagement with my research

Various</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>keynote/invited speaker</gtr:presentationType><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:url>http://www.wchd2013.com/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Oxford Neuroscience Symposium</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>5321F48F-1BF4-487C-A262-7EF5B880A436</gtr:id><gtr:impact>Invitations and talks of this nature serve to enhance engagement with my research

Well attended and my talk was very well received and appreciated</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>keynote/invited speaker</gtr:presentationType><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:url>http://www.medsci.ox.ac.uk/events/4th-annual-oxford-neuroscience-symposium</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presented talk at &quot;20th International Congress of Parkinson's Disease and Movement Disorders, Berlin&quot;</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>611C07E4-F378-448E-93EA-5217C482BA3E</gtr:id><gtr:impact>Presented talk entitled 'Complex phenotypes and genotypes - seeing the wood for the trees, presentation titled Huntington's disease and HD-like disorders'. Generated audience discussion and questions</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Key Advances in Neurodegenerative Disorders Meeting, Royal Society of Medicine</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>FEDC344B-DD5F-4353-BDD4-C4400F2EFBCD</gtr:id><gtr:impact>Presented education talk on HD to healthcare professionals</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Leonard Wolfson UCL-BRU Biomarker Symposium</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>882988B3-87D0-4557-930D-589106FA3D30</gtr:id><gtr:impact>My talk was very well received

No aware of any</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>keynote/invited speaker</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://events.ucl.ac.uk/event/event:odi-h864377g-p7dq89/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Scientific Seminar at the Department of cell and Molecular Biology (CMB)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>7391A234-EE4B-4E71-98E2-67EA57188AFC</gtr:id><gtr:impact>Scientific Seminar at the Department of cell and Molecular Biology (CMB), Karolinska Institute, Stockholm held on 31st May 2013

No</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:url>http://ki.se/ki/jsp/polopoly.jsp?d=27084&amp;a=25977&amp;l=en</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presented talk a Lancet Neurology Conference 2017, London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>54FA3CDA-6068-4697-B477-02FD103E095E</gtr:id><gtr:impact>Presented talk entitled 'Gene silencing approaches for Huntington's disease'. Generated questions and audience discussions.

Prof Tabrizi also organised this meeting</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presented talk at 11th Warsaw International Medical Congress for Young Scientists, Medical University of Warsaw</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2BFD56ED-F411-45E4-B952-CA39729C20DC</gtr:id><gtr:impact>Presented talk entitled ''Meeting the therapeutic challenge in Huntington's disease'. Generated questions and discussion with audience</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presneted talk at CASMI / UCLH BRC / UCL Personalised Medicine Domain Symposium 2017, London, UK</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>0A4DD4E1-2454-403E-8B51-A37EDC8C2F74</gtr:id><gtr:impact>Presented talk entitled 'Cellular and gene therapies'. Generated questions and discussion with audience</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Present talk at European Huntington's Disease Network Conference 2016, The Hague</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0AE657BD-AD7F-4C1B-86D2-E0BCE484E730</gtr:id><gtr:impact>Presented talk entitled 'Gene targeting therapies for Huntington's disease'. Generated talk questions and audience discussion</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>HSG 7th Annual HD Clinical Research Symposium</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>21C2AD99-E45B-4138-9DA8-0737A1D2B1DA</gtr:id><gtr:impact>Invitations and talks of this nature serve to enhance engagement with my research

Various</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>keynote/invited speaker</gtr:presentationType><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:url>http://www.huntington-study-group.org/Events/HSG2013/tabid/274/Default.aspx</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>  AGM &amp; family Conference, invited Guest Lecturer, Telford, Birmingham</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>97E80673-4023-4812-9CE2-27D5E7282899</gtr:id><gtr:impact>Very well attended

Very useful for my research</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presented talk at Association of British Neurologists Special Interest Group Meeting 2017, London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>EEAD3513-9F51-4CD7-B4A9-17181D46BD6E</gtr:id><gtr:impact>Presented talk entitled &amp;quot;Silencing abnormal proteins&amp;quot;. Generated discussion and questions from the audience</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UCL Rare Disease Conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>1C245D22-08E8-460C-8717-AB8E61C6A19B</gtr:id><gtr:impact>Various</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>keynote/invited speaker</gtr:presentationType><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:url>http://www.treat-nmd.eu/events/408/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presented talk at Oxford University Departmental Seminar</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>3B799FF2-D6A9-4A91-98B2-ED12217A2DE8</gtr:id><gtr:impact>Presented talk entitled 'Meeting the Therapeutic Challenge in Huntington's disease'. Generated questions from audience and discussion</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presented talk at Division of Brain Sciences, Imperial College London, Charing Cross Hospital</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CD1091A0-36E2-427E-9FE5-C762FAE61651</gtr:id><gtr:impact>Presented talk entitled &amp;quot;Meeting the Therapeutic Challenge in Huntington's disease&amp;quot;. Talk generated questions and audience participation</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presented talk at Hereditary Disease Foundation, The Milton Wexler Celebration of Life Symposium 2017, Massachusetts</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F36E9398-E0AB-4C41-9C4B-A51CB43DFD5F</gtr:id><gtr:impact>Presented talk entitled 'Early Clinical Development of IONIS-HTTR'. Talk generated questions and audience discussion</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>25th International Symposium on ALS/MND, Brussels</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>FDFF9E17-03BF-4CFF-BE11-59AB2F5E7C21</gtr:id><gtr:impact>Presented educational talk on HD to MNDA members</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>GSK Huntington's Disease Network Advisory meeting</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>388D5DAB-EE40-4465-9681-89882E353434</gtr:id><gtr:impact>very well attended

Good for sharing views</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Marie-Curie Neuromodel Symposium, King's College, London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>59DC2A44-F772-4F00-B161-4DC1DBA1B30B</gtr:id><gtr:impact>Well attended

Good talks by other speakers</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>HD Website</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5581C845-3B78-493E-9CEB-724831B0E6C6</gtr:id><gtr:impact>Articles of this nature serve to enhance engagement with my research

Positive feedback from patients and healthcare professionals</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presented talk at UCL SLMS 2016 Clinical Academic Trainees Symposium, London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>DF3D6E63-86E5-4DEF-B330-A75E1BD06D84</gtr:id><gtr:impact>Presented talk entitled 'Gene silencing approaches for Huntington's disease'. Talk generated questions and audience discussions.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>12th International Symposium on Neural Transplantation and Restoration (INTR12)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0045B0D8-A4C7-4227-8F65-B23D4DFE31DC</gtr:id><gtr:impact>12th International Symposium on Neural Transplantation and Restoration (INTR12) held in Cardiff, UK

NO</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:url>http://www.nectar-eu.net/?q=node/28</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>6620</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Wellcome Trust Institutional Strategic Support Fund</gtr:department><gtr:description>Phenotypic Characterisation of normal and pathogenic human HTT-over-expressing NSC lines for Huntington's Disease.</gtr:description><gtr:end>2015-06-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:fundingRef>097815/Z/11/B0</gtr:fundingRef><gtr:id>317E5C7B-9D3B-4CC2-A2BC-D3C8C5CF45B1</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>163169</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Molecular Characterization of FAN1 Variation in Huntington's disease</gtr:description><gtr:end>2018-06-02</gtr:end><gtr:fundingOrg>CHDI Foundation</gtr:fundingOrg><gtr:id>37A21046-1353-4569-BB69-7CA54148B478</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7B716899-D482-43DA-932D-B0F97C13E0BE"><gtr:id>7B716899-D482-43DA-932D-B0F97C13E0BE</gtr:id><gtr:title>Mutant huntingtin impairs immune cell migration in Huntington disease.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9bd5d1a0d6a0a4f40f13336b701adc5b"><gtr:id>9bd5d1a0d6a0a4f40f13336b701adc5b</gtr:id><gtr:otherNames>Kwan W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/34B76780-E608-4927-8787-463D1387142B"><gtr:id>34B76780-E608-4927-8787-463D1387142B</gtr:id><gtr:title>Mutant huntingtin causes defective actin remodeling during stress: defining a new role for transglutaminase 2 in neurodegenerative disease.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4e27330390007f279cdbe4001d221e52"><gtr:id>4e27330390007f279cdbe4001d221e52</gtr:id><gtr:otherNames>Munsie L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4CAF7320-569D-4B22-A150-840633707408"><gtr:id>4CAF7320-569D-4B22-A150-840633707408</gtr:id><gtr:title>Huntington disease.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Disease primers</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/46a6d340b1c9dd22889424ee21a45141"><gtr:id>46a6d340b1c9dd22889424ee21a45141</gtr:id><gtr:otherNames>Bates GP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2056-676X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1260D3D4-B663-4A44-8127-B03A6F4EC5C9"><gtr:id>1260D3D4-B663-4A44-8127-B03A6F4EC5C9</gtr:id><gtr:title>RNA-Seq of Huntington's disease patient myeloid cells reveals innate transcriptional dysregulation associated with proinflammatory pathway activation.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7c91c19e9fd174710fd50739e4f6ada4"><gtr:id>7c91c19e9fd174710fd50739e4f6ada4</gtr:id><gtr:otherNames>Miller JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4FEEEF16-C795-45F5-80C2-125A9FC1826B"><gtr:id>4FEEEF16-C795-45F5-80C2-125A9FC1826B</gtr:id><gtr:title>Bone marrow transplantation confers modest benefits in mouse models of Huntington's disease.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9bd5d1a0d6a0a4f40f13336b701adc5b"><gtr:id>9bd5d1a0d6a0a4f40f13336b701adc5b</gtr:id><gtr:otherNames>Kwan W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/71DC66CE-CACE-44EC-AF83-A6C6D76C1950"><gtr:id>71DC66CE-CACE-44EC-AF83-A6C6D76C1950</gtr:id><gtr:title>Biomarker development for Huntington's disease.</gtr:title><gtr:parentPublicationTitle>Drug discovery today</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/33cb2cd35605b1d2e4fb89262ae7aa6d"><gtr:id>33cb2cd35605b1d2e4fb89262ae7aa6d</gtr:id><gtr:otherNames>Andre R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1359-6446</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E2E4DA9E-222C-4942-9D71-CA2E748523A0"><gtr:id>E2E4DA9E-222C-4942-9D71-CA2E748523A0</gtr:id><gtr:title>Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells.</gtr:title><gtr:parentPublicationTitle>Journal of neurochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e025e0770ab6775f7402cc2ed94e2155"><gtr:id>e025e0770ab6775f7402cc2ed94e2155</gtr:id><gtr:otherNames>Dobson L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-3042</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/60BA2DA5-25D2-460E-8053-509E7E66D5FD"><gtr:id>60BA2DA5-25D2-460E-8053-509E7E66D5FD</gtr:id><gtr:title>Mutant Huntingtin Does Not Affect the Intrinsic Phenotype of Human Huntington's Disease T Lymphocytes.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7c91c19e9fd174710fd50739e4f6ada4"><gtr:id>7c91c19e9fd174710fd50739e4f6ada4</gtr:id><gtr:otherNames>Miller JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/27EFD64F-3974-4FAB-A2C1-1CECD1F0E2A3"><gtr:id>27EFD64F-3974-4FAB-A2C1-1CECD1F0E2A3</gtr:id><gtr:title>Skeletal muscle atrophy in R6/2 mice - altered circulating skeletal muscle markers and gene expression profile changes.</gtr:title><gtr:parentPublicationTitle>Journal of Huntington's disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/dfa5d414766c2bc1fb01f10fe523e353"><gtr:id>dfa5d414766c2bc1fb01f10fe523e353</gtr:id><gtr:otherNames>Magnusson-Lind A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1879-6397</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3523E388-AD48-402D-B3BF-EE654DB53079"><gtr:id>3523E388-AD48-402D-B3BF-EE654DB53079</gtr:id><gtr:title>A critical evaluation of inflammatory markers in Huntington's Disease plasma.</gtr:title><gtr:parentPublicationTitle>Journal of Huntington's disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e48c5d3a30a258f9307aa4194690131a"><gtr:id>e48c5d3a30a258f9307aa4194690131a</gtr:id><gtr:otherNames>Silajd?ic E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1879-6397</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/589499FF-E3FD-4AD7-8175-67AC1A60B3FD"><gtr:id>589499FF-E3FD-4AD7-8175-67AC1A60B3FD</gtr:id><gtr:title>Analysis of White Adipose Tissue Gene Expression Reveals CREB1 Pathway Altered in Huntington's Disease.</gtr:title><gtr:parentPublicationTitle>Journal of Huntington's disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/19e574f7e92402bb2fe15089a7580366"><gtr:id>19e574f7e92402bb2fe15089a7580366</gtr:id><gtr:otherNames>McCourt AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1879-6397</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/10024D25-ACF8-47CC-A7BF-25BA1F717AAB"><gtr:id>10024D25-ACF8-47CC-A7BF-25BA1F717AAB</gtr:id><gtr:title>A Computational Cognitive Biomarker for Early-Stage Huntington's Disease.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/77ffa6dc59b5c7f6eb866504163d6059"><gtr:id>77ffa6dc59b5c7f6eb866504163d6059</gtr:id><gtr:otherNames>Wiecki TV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/19A4C68F-4733-4ACB-967F-D9003221940B"><gtr:id>19A4C68F-4733-4ACB-967F-D9003221940B</gtr:id><gtr:title>The ubiquitin-proteasome system in neurodegeneration.</gtr:title><gtr:parentPublicationTitle>Antioxidants &amp; redox signaling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/72f6f7a612489664bd7da0da0315c636"><gtr:id>72f6f7a612489664bd7da0da0315c636</gtr:id><gtr:otherNames>McKinnon C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1523-0864</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7C37AA07-A0C4-468A-B276-4882A10652EA"><gtr:id>7C37AA07-A0C4-468A-B276-4882A10652EA</gtr:id><gtr:title>DNA repair pathways underlie a common genetic mechanism modulating onset in polyglutamine diseases.</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9960cd808582e52821f0e586e2ba9176"><gtr:id>9960cd808582e52821f0e586e2ba9176</gtr:id><gtr:otherNames>Bettencourt C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F5B60794-EB06-4C07-BB26-9230079E5F40"><gtr:id>F5B60794-EB06-4C07-BB26-9230079E5F40</gtr:id><gtr:title>8OHdG is not a biomarker for Huntington disease state or progression.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b799ee9492f592d21b66ce4298a8abbd"><gtr:id>b799ee9492f592d21b66ce4298a8abbd</gtr:id><gtr:otherNames>Borowsky B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5BA50D64-847A-4DC0-A21B-C2611577C3AD"><gtr:id>5BA50D64-847A-4DC0-A21B-C2611577C3AD</gtr:id><gtr:title>Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c2ad55e1a2ad1526b8ced1a4945eda9d"><gtr:id>c2ad55e1a2ad1526b8ced1a4945eda9d</gtr:id><gtr:otherNames>Wild EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F04126B8-0F2B-4D5C-8CBF-64217646DBC6"><gtr:id>F04126B8-0F2B-4D5C-8CBF-64217646DBC6</gtr:id><gtr:title>Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2c089bd74059ce969aee77cd687de163"><gtr:id>2c089bd74059ce969aee77cd687de163</gtr:id><gtr:otherNames>Weiss A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2BF6095E-D43B-4B22-B6BC-ADAB435A9232"><gtr:id>2BF6095E-D43B-4B22-B6BC-ADAB435A9232</gtr:id><gtr:title>A critical evaluation of inflammatory markers in Huntington's Disease plasma.</gtr:title><gtr:parentPublicationTitle>Journal of Huntington's disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e48c5d3a30a258f9307aa4194690131a"><gtr:id>e48c5d3a30a258f9307aa4194690131a</gtr:id><gtr:otherNames>Silajd?ic E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1879-6397</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E4DC030E-E1B7-4221-A52A-6DD9AD7488CC"><gtr:id>E4DC030E-E1B7-4221-A52A-6DD9AD7488CC</gtr:id><gtr:title>Reference genes selection for transcriptional profiling in blood of HD patients and R6/2 mice.</gtr:title><gtr:parentPublicationTitle>Journal of Huntington's disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cec506a2b56fdb7a4eea4097ed582b4a"><gtr:id>cec506a2b56fdb7a4eea4097ed582b4a</gtr:id><gtr:otherNames>Diamanti D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1879-6397</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/25C82107-AF93-4FA8-A1C4-220E6548276B"><gtr:id>25C82107-AF93-4FA8-A1C4-220E6548276B</gtr:id><gtr:title>Neurodegeneration</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1cacdbdfdd5b86af962244b0280c0f96"><gtr:id>1cacdbdfdd5b86af962244b0280c0f96</gtr:id><gtr:otherNames>Haider S, Wild E, Tabrizi S</gtr:otherNames></gtr:author></gtr:authors></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7BDB8479-A286-4945-AE9F-A32DBBB18CDA"><gtr:id>7BDB8479-A286-4945-AE9F-A32DBBB18CDA</gtr:id><gtr:title>Huntington's disease: fighting on many fronts.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/33cb2cd35605b1d2e4fb89262ae7aa6d"><gtr:id>33cb2cd35605b1d2e4fb89262ae7aa6d</gtr:id><gtr:otherNames>Andre R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D86DA637-EC5B-4FCF-BE4E-E9AA62ADAA2B"><gtr:id>D86DA637-EC5B-4FCF-BE4E-E9AA62ADAA2B</gtr:id><gtr:title>Large C9orf72 hexanucleotide repeat expansions are seen in multiple neurodegenerative syndromes and are more frequent than expected in the UK population.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/72f7fb44cb0e9d3dbae03fa9e859951a"><gtr:id>72f7fb44cb0e9d3dbae03fa9e859951a</gtr:id><gtr:otherNames>Beck J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B460258A-F377-4743-B73A-3DA3E551BA90"><gtr:id>B460258A-F377-4743-B73A-3DA3E551BA90</gtr:id><gtr:title>Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington's disease.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6f9e725ef6ddd749330cfec9a3d7caf2"><gtr:id>6f9e725ef6ddd749330cfec9a3d7caf2</gtr:id><gtr:otherNames>Bouchard J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6C023682-0615-4C87-992E-586E89155B5D"><gtr:id>6C023682-0615-4C87-992E-586E89155B5D</gtr:id><gtr:title>The ubiquitin-proteasome system in neurodegeneration.</gtr:title><gtr:parentPublicationTitle>Antioxidants &amp; redox signaling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/72f6f7a612489664bd7da0da0315c636"><gtr:id>72f6f7a612489664bd7da0da0315c636</gtr:id><gtr:otherNames>McKinnon C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1523-0864</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B30AB1D9-6EF6-402C-B334-D100E11570F3"><gtr:id>B30AB1D9-6EF6-402C-B334-D100E11570F3</gtr:id><gtr:title>Peripheral inflammation in neurodegeneration.</gtr:title><gtr:parentPublicationTitle>Journal of molecular medicine (Berlin, Germany)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a30e37c21a81f7625f8924ecdce9bed9"><gtr:id>a30e37c21a81f7625f8924ecdce9bed9</gtr:id><gtr:otherNames>Tr?ger U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0946-2716</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/09BDB520-3C00-417C-BFB6-18DCD56F4249"><gtr:id>09BDB520-3C00-417C-BFB6-18DCD56F4249</gtr:id><gtr:title>Prion-mediated neurodegeneration is associated with early impairment of the ubiquitin-proteasome system.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/72f6f7a612489664bd7da0da0315c636"><gtr:id>72f6f7a612489664bd7da0da0315c636</gtr:id><gtr:otherNames>McKinnon C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0001-6322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8065A432-5A44-4684-B1CE-A7ADE97BFB3D"><gtr:id>8065A432-5A44-4684-B1CE-A7ADE97BFB3D</gtr:id><gtr:title>Characterisation of immune cell function in fragment and full-length Huntington's disease mouse models.</gtr:title><gtr:parentPublicationTitle>Neurobiology of disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a30e37c21a81f7625f8924ecdce9bed9"><gtr:id>a30e37c21a81f7625f8924ecdce9bed9</gtr:id><gtr:otherNames>Tr?ger U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0969-9961</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/47A463C3-168C-4C7E-95FE-BD6A253BD734"><gtr:id>47A463C3-168C-4C7E-95FE-BD6A253BD734</gtr:id><gtr:title>Alternative fates of newly formed PrPSc upon prion conversion on the plasma membrane.</gtr:title><gtr:parentPublicationTitle>Journal of cell science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9b4a39284abbd940f6ef1be5b6468337"><gtr:id>9b4a39284abbd940f6ef1be5b6468337</gtr:id><gtr:otherNames>Goold R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0021-9533</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/52EF8497-C00C-46E5-9746-D5EA1B0B6911"><gtr:id>52EF8497-C00C-46E5-9746-D5EA1B0B6911</gtr:id><gtr:title>HTT-lowering reverses Huntington's disease immune dysfunction caused by NF?B pathway dysregulation.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a30e37c21a81f7625f8924ecdce9bed9"><gtr:id>a30e37c21a81f7625f8924ecdce9bed9</gtr:id><gtr:otherNames>Tr?ger U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/72C57569-76BA-45D6-AECD-623340FC0838"><gtr:id>72C57569-76BA-45D6-AECD-623340FC0838</gtr:id><gtr:title>Prion degradation pathways: Potential for therapeutic intervention.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular neurosciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9b4a39284abbd940f6ef1be5b6468337"><gtr:id>9b4a39284abbd940f6ef1be5b6468337</gtr:id><gtr:otherNames>Goold R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1044-7431</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/J003832/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>